文献速递胸部肿瘤放疗放疗物理与技术

立体定向体部放疗后放射性下臂丛神经病:风险汇总分析

Radiation-induced inferior brachial plexopathy after stereotactic body radiotherapy: Pooled analyses of risks.
PubMed 文献 · Radiother Oncol · 2023-02-25

研究基于4项含个体患者数据的系统评价,对顶端肺肿瘤SBRT后放射性臂丛神经病(RIBP)进行正常组织并发症概率(NTCP)建模,提示臂丛最大剂量约32-34 Gy/3次或40-43 Gy/5次时RIBP风险约10%,且风险随臂丛最大剂量增加而升高。

要点

  • 臂丛最大剂量约32-34 Gy/3次或40-43 Gy/5次时,RIBP风险约10%。
  • RIBP风险随臂丛最大剂量增加而升高。
  • SBRT的剂量-反应曲线较常规或中度大分割放疗更平缓。

核心结论

  • SBRT后RIBP风险与臂丛最大剂量存在剂量-反应关系。
  • 与适形度较低的放疗数据比较提示RIBP风险可能存在剂量-体积依赖性,但已发表数据不足以对SBRT后RIBP的剂量-体积指标进行NTCP建模。

研究设计与样本

  • 从既往系统评价中识别4项包含个体患者数据、可用于SBRT治疗顶端肺肿瘤后NTCP建模的研究。
  • 推导两个概率单位NTCP模型:一个基于4项研究(包括221例患者、229个靶区、18个事件);另一个基于3项研究(包括185例患者、192个靶区、11个事件),这些研究对臂丛的勾画方式相似。

主要发现

  • NTCP模型提示臂丛最大剂量约32-34 Gy/3次时RIBP风险约10%。
  • NTCP模型提示臂丛最大剂量约40-43 Gy/5次时RIBP风险约10%。
  • RIBP风险随臂丛最大剂量增加而升高。
  • 与既往发表的乳腺癌、肺癌和头颈部癌常规分割或中度大分割放疗数据相比,SBRT在臂丛最大剂量>90-100 Gy(2 Gy等效剂量)时剂量-反应曲线更平缓。

关键数值与推荐

  • 臂丛最大剂量约32-34 Gy/3次对应RIBP风险约10%。
  • 臂丛最大剂量约40-43 Gy/5次对应RIBP风险约10%。
  • SBRT的剂量-反应曲线在臂丛最大剂量>90-100 Gy(2 Gy等效剂量)时较常规或中度大分割放疗更平缓。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 已发表数据不足以对SBRT后RIBP的剂量-体积指标进行NTCP建模。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Radiation-induced brachial plexopathy (RIBP), resulting in symptomatic motor or sensory deficits of the upper extremity, is a risk after exposure of the brachial plexus to therapeutic doses of radiation. We sought to model dosimetric factors associated with risks of RIBP after stereotactic body radiotherapy (SBRT). METHODS: From a prior systematic review, 4 studies were identified that included individual patient data amenable to normal tissue complication probability (NTCP) modelling after SBRT for apical lung tumors. Two probit NTCP models were derived: one from 4 studies (including 221 patients with 229 targets and 18 events); and another from 3 studies (including 185 patients with 192 targets and 11 events) that similarly contoured the brachial plexus. RESULTS: NTCP models suggest ≈10% risks associated with brachial plexus maximum dose (Dmax) of ∼32-34 Gy in 3 fractions and ∼40-43 Gy in 5 fractions. RIBP risks increase with increasing brachial plexus Dmax. Compared to previously published data from conventionally-fractionated or moderately-hypofractionated radiotherapy for breast, lung and head and neck cancers (which tend to utilize radiation fields that circumferentially irradiate the brachial plexus), SBRT (characterized by steep dose gradients outside of the target volume) exhibits a much less steep dose-response with brachial plexus Dmax > 90-100 Gy in 2-Gy equivalents. CONCLUSIONS: A dose-response for risk of RIBP after SBRT is observed relative to brachial plexus Dmax. Comparisons to data from less conformal radiotherapy suggests potential dose-volume dependences of RIBP risks, though published data were not amenable to NTCP modelling of dose-volume measures associated with RIBP after SBRT.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Milano MT, Mavroidis P, Ryckman J, et al. Radiation-induced inferior brachial plexopathy after stereotactic body radiotherapy: Pooled analyses of risks. Radiother Oncol. 2023. PMID: 36842665. doi:10.1016/j.radonc.2023.109583

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。